» Articles » PMID: 37769433

Distinct HLA Associations with Autoantibody-defined Subgroups in Idiopathic Inflammatory Myopathies

Abstract

Background: In patients with idiopathic inflammatory myopathies (IIM), autoantibodies are associated with specific clinical phenotypes suggesting a pathogenic role of adaptive immunity. We explored if autoantibody profiles are associated with specific HLA genetic variants and clinical manifestations in IIM.

Methods: We included 1348 IIM patients and determined the occurrence of 14 myositis-specific or -associated autoantibodies. We used unsupervised cluster analysis to identify autoantibody-defined subgroups and logistic regression to estimate associations with clinical manifestations, HLA-DRB1, HLA-DQA1, HLA-DQB1 alleles, and amino acids imputed from genetic information of HLA class II and I molecules.

Findings: We identified eight subgroups with the following dominant autoantibodies: anti-Ro52, -U1RNP, -PM/Scl, -Mi2, -Jo1, -Jo1/Ro52, -TIF1γ or negative for all analysed autoantibodies. Associations with HLA-DRB1∗11, HLA-DRB1∗15, HLA-DQA1∗03, and HLA-DQB1∗03 were present in the anti-U1RNP-dominated subgroup. HLA-DRB1∗03, HLA-DQA1∗05, and HLA-DQB1∗02 alleles were overrepresented in the anti-PM/Scl and anti-Jo1/Ro52-dominated subgroups. HLA-DRB1∗16, HLA-DRB1∗07 alleles were most frequent in anti-Mi2 and HLA-DRB1∗01 and HLA-DRB1∗07 alleles in the anti-TIF1γ subgroup. The HLA-DRB1∗13, HLA-DQA1∗01 and HLA-DQB1∗06 alleles were overrepresented in the negative subgroup. Significant signals from variations in class I molecules were detected in the subgroups dominated by anti-Mi2, anti-Jo1/Ro52, anti-TIF1γ, and the negative subgroup.

Interpretation: Distinct HLA class II and I associations were observed for almost all autoantibody-defined subgroups. The associations support autoantibody profiles use for classifying IIM which would likely reflect underlying pathogenic mechanisms better than classifications based on clinical symptoms and/or histopathological features.

Funding: See a detailed list of funding bodies in the Acknowledgements section at the end of the manuscript.

Citing Articles

An update on autoantibodies in the idiopathic inflammatory myopathies.

Allameen N, Ramos-Lisbona A, Wedderburn L, Lundberg I, Isenberg D Nat Rev Rheumatol. 2024; 21(1):46-62.

PMID: 39609638 DOI: 10.1038/s41584-024-01188-4.


Recent Updates on the Pathogenesis of Inflammatory Myopathies.

Musai J, Mammen A, Pinal-Fernandez I Curr Rheumatol Rep. 2024; 26(12):421-430.

PMID: 39316320 PMC: 11527972. DOI: 10.1007/s11926-024-01164-7.


Unraveling the Genetics of Shared Clinical and Serological Manifestations in Patients With Systemic Inflammatory Autoimmune Diseases.

Bianchi M, Kozyrev S, Notarnicola A, Sandling J, Pettersson M, Leonard D Arthritis Rheumatol. 2024; 77(2):212-225.

PMID: 39284741 PMC: 11782108. DOI: 10.1002/art.42988.


Celiac disease prevalence in patients with idiopathic inflammatory myopathies, a cross-sectional study.

Gonzalez-Leal R, Torres-Ruiz J, Mejia-Dominguez N, Nunez-Alvarez C, Perez-Gonzalez B, Uscanga-Dominguez L Clin Rheumatol. 2024; 43(7):2253-2260.

PMID: 38842744 DOI: 10.1007/s10067-024-07020-4.